Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Select Medical Holdings (SEM) Cash & Equivalents (2018 - 2026)

Select Medical Holdings (SEM) has disclosed Cash & Equivalents for 9 consecutive years, with $25.7 million as the latest value for Q1 2026.

  • For Q1 2026, Cash & Equivalents fell 51.74% year-over-year to $25.7 million; the TTM value through Mar 2026 reached $25.7 million, down 51.74%, while the annual FY2025 figure was $26.5 million, 55.57% down from the prior year.
  • Cash & Equivalents hit $25.7 million in Q1 2026 for Select Medical Holdings, down from $26.5 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $191.5 million in Q3 2024 and bottomed at $25.7 million in Q1 2026.
  • Average Cash & Equivalents over 5 years is $83.5 million, with a median of $83.7 million recorded in 2023.
  • Year-over-year, Cash & Equivalents crashed 88.22% in 2022 and then skyrocketed 147.25% in 2024.
  • Select Medical Holdings' Cash & Equivalents stood at $97.9 million in 2022, then crashed by 46.24% to $52.6 million in 2023, then increased by 13.42% to $59.7 million in 2024, then tumbled by 55.57% to $26.5 million in 2025, then fell by 3.17% to $25.7 million in 2026.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $25.7 million, $26.5 million, and $60.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.